Certain HIV Medications to Discontinue
ViiV Healthcare, a GlaxoSmithKline company, communicated to the FDA that several HIV medications they manufacture will be discontinued by the end of 2023. Epzicom® (abacavir sulfate, lamivudine) 600/300mg tablets and Trizivir® (abacavir sulfate, lamivudine, zidovudine) 300mg/150mg/300mg tablets will be discontinued but will have generics on the market. Lexiva® (fosamprenavir calcium) 700 mg tablets and the 50mg/mL oral solution (225mL) will be discontinued; generics are available for the tablets, but not the oral solution. Selzentry® (maraviroc) 25mg and 75mg tablets will be discontinued, however 150mg dose, 300 mg dose, and oral solution will not cease production. Tivicay® (dolutegravir) 10mg and 25mg tablets will be discontinued without a generic product available at those doses; 50mg tablets and Tivicay PD 5mg will remain available as brand drugs. Ziagen® (abacavir sulfate) 300mg tablets will cease distribution, but the oral solution will be available. Notable for workers’ comp, some of the abovementioned medications are included in the U.S. Public Health Service’s guidelines for managing occupational exposure to HIV.
